The official launch of Le-Vel’s exosome-based skin system, XERA, on Dec. 16 marks what the company describes as a new era in skin repair, restoration, and renewal.
“XERA represents a defining moment for our brand and the next evolution of Le-Vel innovation,” said Jason Camper, co-founder and CEO of Le-Vel, the company behind the premium health and wellness system THRIVE. “We’ve spent years pushing boundaries in nutritional science, and now we’re doing the same for skin technology. This exosome-powered system doesn’t just improve the appearance of your skin; it activates your skin’s natural ability to repair and rejuvenate. It’s truly a new era for skin rejuvenation and age-defying transformation.”
The Rise of Exosomes
The inclusion of exosomes in skin care is becoming increasingly prevalent in regenerative aesthetic dermatology. These lipid-bound vesicles have been studied for their potential to brighten and strengthen the skin, reduce inflammation, and support long-term skin wellness. Originally explored in experimental stem cell research, exosomes are cell-derived, anti-aging signalers that deliver messages to fibroblasts to produce more collagen and elastin.
As interest in regenerative approaches grows, medical aesthetic professionals have begun incorporating exosomes into a variety of treatments to stimulate cell regeneration and boost collagen production. Beyond therapeutic use, exosomes are also gaining traction in preventive skin maintenance, with clinical trials showing promising results for proactive skin health and resilience strategies.
One of aesthetic dermatology’s most notable trends in 2025 has been a shift toward regenerative science and long-term skin health. Exosome-based technologies are contributing to this movement, helping redirect patient interest away from short-term cosmetic fixes toward biologically driven regeneration. Aesthetics and medical dermatology are increasingly being viewed as complementary disciplines with exosomes playing a role in bridging the gap.
A Three-Step System
While clinical trials of exosomes continue and industry experts urge cautious optimism, Le-Vel, a cloud-based company serving more than 10 million customers worldwide, has moved ahead with its XERA launch.
The XERA system consists of three products designed to maximize the potential of the exosomes it contains. The XERA Dermal Prepping Cleanser primes the skin, prepping the surface by removing impurities and preparing the skin for subsequent products. The XERA Exosome Daily Repair Hydrator combines exosomes and peptides to support hydration, while the Tightening Repair Lift also uses exosome technology with a focus on skin firming and hydration.
Conclusion
XERA, which made its initial debut in October in Punta Cana, Dominican Republic during Le-Vel’s Lifestyle Getaway, has undergone months of beta-testing and preorders leading up to its official release. As no exosome-based products have yet secured FDA approval, practitioners and patients are advised to exercise caution when using or recommending skincare that utilizes exosomes.
Florida-based plastic surgeon, Andrew H. Rosenthal, MD, explained that while exosome therapy may hold exciting potential, more research and regulation are needed to fully establish its safety, efficacy, and appropriate clinical use.
“It’s in its infancy; more is going to come, and it seems like it’s going to be a very promising technology,” Dr. Rosenthal said. “There are a lot of people running to do this, but it’s going to be a bit before we have things that are both efficacious and safe.”
